Search

Zentalis Pharmaceuticals Inc

Geschlossen

5 -1.96

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.99

Max

5.11

Schlüsselkennzahlen

By Trading Economics

Einkommen

-136K

-35M

EPS

-0.503

Angestellte

106

EBITDA

2.2M

-35M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+30.53% upside

Dividenden

By Acuity

Nächstes Ergebnis

4. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

34M

329M

Vorheriger Eröffnungskurs

6.96

Vorheriger Schlusskurs

5

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Juli 2026, 23:56 UTC

AAR Corp shares are trading higher in after-market hours, reflecting typical fluctuations around the midpoint of their one-month range.

20. Juli 2026, 23:56 UTC

Nucor Corp shares are higher in after-market trading, reflecting routine performance. No specific news was identified to explain the price movement.

20. Juli 2026, 23:56 UTC

Epam Systems Inc. shares declined in after-market trading, aligning with a broader economic backdrop following a slight decrease in the Conference Board's leading economic index.

20. Juli 2026, 23:56 UTC

Definitive Healthcare Corp shares are lower in after-market hours, continuing a trend from recent sessions amid broader market uncertainties and weak economic data.

20. Juli 2026, 23:56 UTC

News

Brookdale Senior Living announced its second-quarter 2026 earnings release dates, boosting investor sentiment. Shares are trading higher in after-market hours.

20. Juli 2026, 23:56 UTC

Delek US Holdings Inc shares are higher in after-market hours, continuing a directional advance from earlier in the session. No specific news was identified.

20. Juli 2026, 23:56 UTC

Harley-Davidson Inc shares are higher in after-market trading, recovering from an earlier dip and positioning above the 20-day moving average.

20. Juli 2026, 23:56 UTC

News

Valero Energy Corp gains in after-market trading on strong earnings forecast, with projected EPS of $9.81 and revenue expectations of $35.95 billion.

20. Juli 2026, 23:56 UTC

Beam Therapeutics Inc is higher in after-market trading, showing notable strength since Monday's close. No specific news was identified to explain the movement.

20. Juli 2026, 23:56 UTC

Correlated Moves

Teradyne Inc shares are higher in after-market trading, recovering from earlier session lows, as the Nasdaq 100 Index also moves up.

20. Juli 2026, 23:56 UTC

NextDecade Corp. shows a slight uptick in after-market trading, remaining stable around the midpoint of its one-month trading range.

20. Juli 2026, 23:56 UTC

Geron Corp shares are lower in after-market hours, continuing a decline since Monday's close amid broader market uncertainties and a drop in the leading economic index.

20. Juli 2026, 23:56 UTC

Marathon Petroleum shares are higher in after-market trading, maintaining strength above the 20-day moving average despite a decline in the leading economic index.

20. Juli 2026, 23:56 UTC

Salesforce Inc. shares remained roughly flat after market hours. The Conference Board reported a modest decline in its leading economic index for June.

20. Juli 2026, 23:56 UTC

Aurora Innovation Inc shares are lower in after-market hours, with no specific news identified. Broader economic concerns include a decline in the leading economic index.

20. Juli 2026, 23:51 UTC

Correlated Moves
ETF Constituents

Vanguard FTSE Emerging Markets ETF rises in after-market trading, supported by strong performances from Taiwan Semiconductor and HDFC Bank, despite remaining near recent lows.

20. Juli 2026, 23:51 UTC

Sabre Corp shares are lower in after-market hours, continuing a decline since Monday's close and remaining below their 20-day moving average.

20. Juli 2026, 23:51 UTC

Daktronics Inc shares are higher in after-market hours, reflecting strong momentum and trading near the upper end of their one-month range.

20. Juli 2026, 23:51 UTC

Reinsurance Group of America shares are higher in after-market hours, supported by a significant rise in the reinsurance sub-sector. The price is near its one-month high.

20. Juli 2026, 23:51 UTC

CenterPoint Energy Inc shares are higher in after-market trading, reflecting a steady upward movement since Monday's close amid rising Treasury yields and economic index concerns.

20. Juli 2026, 23:51 UTC

Geo Group Inc shares are lower in after-market hours, reflecting broader market concerns over rising Treasury yields and a decline in the leading economic index.

20. Juli 2026, 23:51 UTC

HealthStream Inc shares are lower in after-market trading. Broader market concerns include rising Treasury yields and a decline in the Conference Board's leading economic index.

20. Juli 2026, 23:51 UTC

CEVA Inc shares rose in after-market trading, recovering from earlier volatility and contrasting with four consecutive lower closes. The stock remains below its 20-day moving average.

20. Juli 2026, 23:51 UTC

News
Correlated Moves

Ally Financial shares are lower in after-market trading despite the board declaring a quarterly cash dividend of $0.30 per share.

20. Juli 2026, 23:51 UTC

Constellation Brands Inc shares are higher in after-market hours, with no specific news identified to explain the movement. Trading activity has been notably active.

20. Juli 2026, 23:51 UTC

Amkor Technology Inc shares are trading higher in after-market hours, despite no specific news and increased caution in the broader market.

20. Juli 2026, 23:51 UTC

Mexico's Upcoming Balance of Trade Data on July 27, 2026, Expected to Reflect Economic Health Amid Geopolitical Tensions and Investment Recovery Signals.

20. Juli 2026, 23:51 UTC

Australia's Full-Time Employment Change Report Set for July 23, 2026: Market Eyes Job Growth Amid Economic Uncertainty.

20. Juli 2026, 23:51 UTC

Australia's July 2026 employment change forecast predicts a modest increase of 15,000 jobs amid mixed labor market sentiment and potential impacts from skilled migration reforms.

20. Juli 2026, 23:51 UTC

Australia's unemployment rate for June 2026 is set to be released on July 23, with a forecast of 4.4%, amid cautious optimism in local markets despite global economic uncertainties.

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

30.53% Vorteil

12-Monats-Prognose

Durchschnitt 6.67 USD  30.53%

Hoch 10 USD

Tief 4 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

4

Buy

3

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat